The specialty pharma company issued a cryptic press release this morning saying that it learned last night “some adminstrative activity” may soon occur regarding an application for a patent extension on its Angiomax blood thinner.

But no one knows if it will be good or bad news. In a statement, Clive Meanwell said he has “limited information.” This comes just one week after the company announced plans to sell 6 million shares.

The U.S. Patent and Trademark Office had rejected the company’s application to extend the Angiomax patent beyond 2010 because it filing was a day late. Meanwell then sought help from Washington for legislation that would extend filings.

Shares are off 3.7 percent as of noon on heavy trading volume.[tags]Medicines Company, patent legislation[/tags]